Discover the Latest in Cancer Research: Rain Therapeutics to Present at Prestigious EORTC-AACR-NCI Symposium
Rain Therapeutics: Advancing Precision Oncology Rain Therapeutics Announces a Poster Presentation at the 34th EORTC/AACR/NCI Symposium NEWARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53,…